Veeva Systems Inc
veeva.comVeeva Systems Inc. (NYSE: VEEV) is a life sciences cloud software company that provides industry-specific software, data, and business consulting solutions to pharmaceutical, biotechnology, and other life sciences companies. Revenue comes primarily from subscription fees for cloud software and data products, which constituted 84% of total revenues for the fiscal year ended January 31, 2026, with professional services and other revenues making up the remaining 16%. Veeva serves customers across two broad solution areas: Commercial Solutions, covering CRM, medical, and marketing products, and R&D and Quality Solutions, covering clinical, regulatory, safety, and quality applications built on the proprietary Veeva Vault platform. As of January 31, 2026, Veeva served 1,552 total customers, including 767 Commercial Solutions customers and 1,196 R&D and Quality Solutions customers. The company sells exclusively to the life sciences industry through a direct sales organization and hosts its products on infrastructure provided by Amazon Web Services and Salesforce.
Products & Services
Commercial Cloud: Veeva Vault CRM Suite (next-generation CRM built on Vault platform for sales, marketing, medical, and service teams), Veeva CRM (legacy CRM built on Salesforce platform, supported through December 31, 2029), Veeva Medical. Development Cloud: Veeva Vault platform hosting clinical, regulatory, and safety applications including Veeva Clinical Platform for clinical trial execution. Data and consulting: proprietary data products and Veeva Business Consulting covering commercial strategy and R&D process optimization.
Revenue Model
Subscription fees (84% of total revenues, FY2026 ended January 31, 2026) billed annually or quarterly in advance, covering access to cloud software and data solutions. Professional services and other revenues (16% of total revenues, FY2026) cover implementation, configuration, managed services, speakers bureau logistics, and Veeva Business Consulting engagements. Subscription revenues are recognized ratably over the contract term.
Customers & Markets
Life sciences companies globally, including large global pharmaceutical and biotechnology companies and smaller pre-commercial stage companies. As of January 31, 2026: 1,552 total customers, 767 Commercial Solutions customers, 1,196 R&D and Quality Solutions customers. Some customers subscribe to both solution areas. End markets span drug R&D (clinical, regulatory, safety, quality) through commercialization (field sales, medical affairs, marketing).
Geographic Exposure
Products hosted in data centers in the United States, European Union, Japan, South Korea, Singapore, Australia, Brazil, and China (China-specific products hosted locally). Sells globally to the life sciences industry through a direct sales organization.
Loading...
